Regeneron UK Limited has announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo (cemiplimab) for use on ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

The approval means that Libtayo is now the first immunotherapy approved in Europe to treat advanced cervical cancer, regardless of PD-L1 expression or tumour histology. The fourth leading cause of ...

Sanofi and Regeneron’s checkpoint inhibitor Libtayo has become the first immunotherapy to improve survival when used as a second-line therapy in cervical cancer, setting up regulatory filings ...

and advanced cervical cancer. In the?US, the generic name for Libtayo in its approved?indications is cemiplimab-rwlc, with rwlc as the suffix designated in accordance with Nonproprietary Naming of ...

A mother of three was blindsided by a cervical cancer diagnosis just days before her 30th birthday — despite experiencing ...

Chemoradiation with platinum-based chemo is standard for locally advanced cervical cancer, but adverse events drive ...

Cervical cancer often develops silently, making it essential for women to recognise its early warning signs and seek timely medical attention. Cervical cancer is one of the most common cancers in ...

A new report explores the disproportionately high death rate among Black women in the Delta from cervical cancer.

A new research paper was published in Oncoscience’s Volume 12 on January 20, 2025, titled “Maternal, delivery and neonatal ...

With proper screening, vaccination, and awareness, we can significantly reduce cervical cancer cases. It is crucial to educate people because cervical cancer is one of the few cancers in women ...